share_log

EyePoint Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

EyePoint Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

EyePoint Pharmaceuticals | 10-Q：2024財年三季報
美股SEC公告 ·  2024/11/07 13:08

Moomoo AI 已提取核心訊息

EyePoint Pharmaceuticals reported Q3 2024 total revenue of $10.5 million, down 31% from $15.2 million in Q3 2023. The decline was primarily driven by lower product sales and license revenue following the transfer of YUTIQ rights to ANI Pharmaceuticals. Product sales decreased 19% to $0.7 million, while license and collaboration revenue fell 32% to $9.6 million.Research and development expenses increased 70% to $29.5 million, reflecting expanded clinical trials for DURAVYU, including Phase 3 studies for wet AMD and increased personnel costs. The company reported positive interim 16-week data from the Phase 2 VERONA trial of DURAVYU for diabetic macular edema, showing improved visual acuity compared to aflibercept control.The company ended Q3 with $253.8 million in cash and investments, subsequently raising an additional $161 million through a public offering in October 2024. Management expects current funding to support operations into 2027, as it advances late-stage clinical development of DURAVYU and other pipeline candidates. Net loss for Q3 widened to $29.4 million from $12.6 million year-over-year.
EyePoint Pharmaceuticals reported Q3 2024 total revenue of $10.5 million, down 31% from $15.2 million in Q3 2023. The decline was primarily driven by lower product sales and license revenue following the transfer of YUTIQ rights to ANI Pharmaceuticals. Product sales decreased 19% to $0.7 million, while license and collaboration revenue fell 32% to $9.6 million.Research and development expenses increased 70% to $29.5 million, reflecting expanded clinical trials for DURAVYU, including Phase 3 studies for wet AMD and increased personnel costs. The company reported positive interim 16-week data from the Phase 2 VERONA trial of DURAVYU for diabetic macular edema, showing improved visual acuity compared to aflibercept control.The company ended Q3 with $253.8 million in cash and investments, subsequently raising an additional $161 million through a public offering in October 2024. Management expects current funding to support operations into 2027, as it advances late-stage clinical development of DURAVYU and other pipeline candidates. Net loss for Q3 widened to $29.4 million from $12.6 million year-over-year.
EyePoint Pharmaceuticals報告2024年第三季度總營業收入爲1050萬美金，比2023年第三季度的1520萬美金下降了31%。這一下降主要是由於產品銷售和許可收入較低，因爲YUTIQ的權利轉讓給了ANI Pharmaceuticals。產品銷售下降了19%，降至70萬美金，而許可和合作收入則下降了32%，降至960萬美金。研究和開發支出增加了70%，達到2950萬美金，反映出DURAVYU擴展臨牀試驗的情況，包括針對溼性AMD的第三階段研究和人員成本增加。該公司報告了來自DURAVYU針對糖尿病性黃斑水腫的第二階段VERONA試驗的積極中期16週數據，顯示出相比於阿柏西普...展開全部
EyePoint Pharmaceuticals報告2024年第三季度總營業收入爲1050萬美金，比2023年第三季度的1520萬美金下降了31%。這一下降主要是由於產品銷售和許可收入較低，因爲YUTIQ的權利轉讓給了ANI Pharmaceuticals。產品銷售下降了19%，降至70萬美金，而許可和合作收入則下降了32%，降至960萬美金。研究和開發支出增加了70%，達到2950萬美金，反映出DURAVYU擴展臨牀試驗的情況，包括針對溼性AMD的第三階段研究和人員成本增加。該公司報告了來自DURAVYU針對糖尿病性黃斑水腫的第二階段VERONA試驗的積極中期16週數據，顯示出相比於阿柏西普對照組的視力改善。該公司在第三季度末現金和投資達到25380萬美金，隨後於2024年10月通過公開募股再融資16100萬美金。管理層預計當前資金將支持運營至2027年，同時推進DURAVYU及其他管線候選藥物的後期臨牀開發。第三季度淨虧損擴大至2940萬美金，較上年同期的1260萬美金有所增加。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

獨立文件7  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Corcept醫療
    CORT
    -- 101.750
    bluebird bio
    BLUE
    -- 5.200
    ABVC BioPharma
    ABVC
    -- 0.9943
    NLS Pharmaceutics
    NLSP
    -- 1.4758
    DBV Technologies
    DBVT
    -- 6.800
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    中概股財報季火熱：驚喜盈利能否延續漲勢？
    1. 哪些行業可能成為本輪財報季的市場焦點？ 2. 在政府強調科技創新和可持續發展的背景下，你認為哪些行業具有最大的增長潜力？ 展开
    中國兩會：會議前後股票價格變動的關鍵要點